These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 22852138)
1. FDA paves the way for pre-exposure HIV prophylaxis. Holmes D Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138 [No Abstract] [Full Text] [Related]
2. Still a long wait for approved HIV-protective gel. Bateman C S Afr Med J; 2010 Sep; 100(9):560, 562. PubMed ID: 20822637 [No Abstract] [Full Text] [Related]
3. How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention. Haire B; Kaldor J; Jordens CF Am J Bioeth; 2012; 12(6):21-30. PubMed ID: 22650457 [TBL] [Abstract][Full Text] [Related]
5. A perspective on progress and gaps in HIV prevention science. Kiser PF; Mesquita PM; Herold BC AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871 [TBL] [Abstract][Full Text] [Related]
6. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. Keller SB; Smith DM AIDS; 2011 Nov; 25(18):2308-10. PubMed ID: 22067201 [No Abstract] [Full Text] [Related]
7. Recent FDA approvals and changes. AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092 [No Abstract] [Full Text] [Related]
8. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. McCormack S; Fidler S; Fisher M; ; Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679 [No Abstract] [Full Text] [Related]
9. Preexposure prophylaxis for HIV infection. Steinbrook R JAMA; 2012 Sep; 308(9):865-6. PubMed ID: 22820712 [No Abstract] [Full Text] [Related]
10. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466 [TBL] [Abstract][Full Text] [Related]
11. [Pre-exposure prophylaxis for HIV transmission? No, unless]. Boeke AJ; Heijnen AM Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404 [TBL] [Abstract][Full Text] [Related]
12. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. Gazzard BG Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093 [TBL] [Abstract][Full Text] [Related]
13. Single-tablet Quad regimen achieves high rate of virologic suppression. AIDS Patient Care STDS; 2010 Mar; 24(3):197. PubMed ID: 20214488 [No Abstract] [Full Text] [Related]
14. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402 [TBL] [Abstract][Full Text] [Related]
15. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Karim SS; Kashuba AD; Werner L; Karim QA Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939 [No Abstract] [Full Text] [Related]
16. Labeling changes for tenofovir. AIDS Patient Care STDS; 2004 Jan; 18(1):55. PubMed ID: 15006195 [No Abstract] [Full Text] [Related]
17. Perceptions of emtricitabine-tenofovir in HIV PrEP. Kruse L; Stover K; Henderson H HIV Clin; 2014; 26(1):1, 4-7. PubMed ID: 24855688 [No Abstract] [Full Text] [Related]
18. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299 [TBL] [Abstract][Full Text] [Related]
19. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1]. Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575 [TBL] [Abstract][Full Text] [Related]
20. No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla. Burger D; van Luin M; Bosch M; van der Ven A; Brouwer AM; Keuter M; Dofferhoff T; Koopmans PP J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e12-3. PubMed ID: 20647821 [No Abstract] [Full Text] [Related] [Next] [New Search]